Results 121 to 130 of about 147,637 (252)

Urinary Dysfunction in Myasthenic Syndromes: A Scoping Review of Clinical Features and Treatment‐Related Associations

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Urinary dysfunction has been reported in association with myasthenic syndromes, including myasthenia gravis (MG), Lambert–Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS), but evidence regarding its prevalence, clinical impact, pathophysiology, and management remains limited.
Julia M. Augustin   +13 more
wiley   +1 more source

Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination

open access: yesNeurology and Clinical Neuroscience, EarlyView.
ABSTRACT Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated ...
Hiroyuki Takenaka   +3 more
wiley   +1 more source

Chronic Pruritic Papular Eruption in an Elderly Man

open access: yes
JEADV Clinical Practice, EarlyView.
Filipe Monteiro   +6 more
wiley   +1 more source

Bell's Palsy in 11,255 Cases: Cardiometabolic Associations in a Population‐Based Healthcare Database

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To estimate Bell's palsy incidence and evaluate the prevalence and associations with diabetes and other cardiometabolic conditions. Study Design Population‐based cohort study. Setting Clalit Health Services, the largest healthcare provider organization in Israel (2005‐2022).
Tomer Boldes   +5 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

open access: yesThe Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi   +8 more
wiley   +1 more source

Management of De Novo miN1 Prostate Cancer in the PSMA‐PET Era

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is reshaping nodal staging in prostate cancer by detecting regional lymph node metastases with greater accuracy than conventional imaging. This has created a new cohort of patients with N1M0 disease detectable only on advanced imaging, raising important ...
Thomas McMaster   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy